Ivarmacitinib Eased Refractory PCA: Case Report - Takeaways - MDSpire

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

  • By

  • Andrea Surnit

  • May 20, 2026

  • 4 min

Share

  • 1

    A 65-year-old man with refractory primary cutaneous amyloidosis showed rapid improvement after off-label treatment with ivarmacitinib.

  • 2

    The patient experienced significant pruritus relief and lesion improvement within one month of starting ivarmacitinib.

  • 3

    Histopathologic examination confirmed the diagnosis of primary cutaneous amyloidosis, showing characteristic amyloid deposits.

  • 4

    Ivarmacitinib, a selective JAK1 inhibitor, may target multiple inflammatory pathways involved in pruritus and T helper 2 inflammation.

  • 5

    The study highlights the potential of ivarmacitinib for treating isolated primary cutaneous amyloidosis, warranting further research.

Original Source(s)

Ivarmacitinib Eased Refractory PCA: Case Report

  • by Andrea Surnit

  • May 20, 2026

Related Content

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

Non-invasive detection of pediatric atopic dermatitis based on fecal microbiota and metabolite profiles: a diagnostic approach